eMed CEO Linda Yaccarino and Chief Wellness Officer Tom Brady reveal their strategy to revolutionize healthcare by expanding access to GLP-1 medications. Yaccarino highlights eMed’s 90% adherence rate through AI and clinical support, addressing chronic diseases like heart and liver conditions. Brady emphasizes the importance of health and wellness, aiming to democratize access to essential medical treatments and support long-term behavioral change for employees.